Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680]
Gynecologic Oncology（2023）
关键词
ovarian cancer”,immunotherapy,homologous recombination proficient,gynecologic oncology volume
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要